The radiotherapy planning CT-based multi-omics for predicting the radiation pneumonitis in lung cancer patients: A multi-center study

Author:

Niu Lishui1,Chu Xianjing1,Yang Xianghui2,Zhao Hongxiang3,Chen Liu1,Deng Fuxing1,Liang Zhan1,Jing Di1,Zhou Rongrong1

Affiliation:

1. Xiangya Hospital Central South University

2. Changsha Central Hospital

3. Beijing University of Posts and Telecommunications

Abstract

Abstract Background To predict the risk of radiation pneumonitis (RP), deep learning (DL) models were built to stratify lung cancer patients. Our study also investigated the impact of RP on survival. Methods This study retrospectively collected 100 RP and 99 matched non-RP lung cancer patients treated with radiotherapy from two independent centers. These patients were randomly divided into training (n = 175) and validation cohorts (n = 24). The radiomics and dosiomics features were extracted from radiation planning computed tomography (CT). Clinical information was retrospectively collected from the electronic medical record database. All features were screened by LASSO cox regression. A multi-omics prediction model was developed by the optimal algorithm and estimated the area under the receiver operating characteristic curve (AUC). Overall survival (OS) between RP, non-RP, mild-RP, and severe-RP groups was analyzed by the Kaplan-Meier method. Results There were eventually selected 16 radiomics features, 2 dosiomics features, and 1 clinical feature to build the best multi-omics model. GLRLM_Gray Level Non Uniformity Normalized and GLCM_MCC from PTV were essential dosiomics features, and T stage was a paramount clinical feature. The optimal performance for predicting RP was the AUC of testing set [0.94, 95% confidence interval (CI) (0.939-1.000)] and the AUC of external validation set [0.92, 95% CI (0.80-1.00)]. All RP patients were divided into mild-RP and severe-RP group according to RP grade (≤ 2 grade and > 2 grade). The median OS was 31 months (95% CI, 28–39) for non-RP group compared with 49 months (95% CI, 36-NA) for RP group (HR = 0.53, P = 0.0022). Among RP subgroup, the median OS was 57months (95% CI, 47-NA) for mild-RP and 25 months (95% CI, 29-NA) for severe-RP, and mild-RP group exhibited a longer OS (HR = 3.72, P < 0.0001). Conclusion The multi-omics model contributed to improvement in the accuracy of the RP prediction. Interestingly, this study also demonstrated that compared with non-RP patients, RP patients displayed longer OS, especially mild-RP.

Publisher

Research Square Platform LLC

Reference37 articles.

1. Cancer statistics, 2022;Siegel RL;CA Cancer J Clin,2022

2. Radiotherapy treatment for lung cancer: Current status and future directions;Vinod SK;Respirology,2020

3. Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of lung cancer;Bezjak A;Clin Oncol (R Coll Radiol),2012

4. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial [published online ahead of print, 2022 Aug 9];Garassino MC;J Thorac Oncol,2022

5. Radiation-Induced Lung Injury (RILI);Giuranno L;Front Oncol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3